Free Trial
NASDAQ:OPRX

OptimizeRx (OPRX) Stock Price, News & Analysis

OptimizeRx logo
$17.25 +1.11 (+6.88%)
Closing price 04:00 PM Eastern
Extended Trading
$17.24 0.00 (-0.03%)
As of 05:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About OptimizeRx Stock (NASDAQ:OPRX)

Key Stats

Today's Range
$15.97
$17.30
50-Day Range
$12.48
$17.59
52-Week Range
$3.78
$18.22
Volume
367,815 shs
Average Volume
381,913 shs
Market Capitalization
$320.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.81
Consensus Rating
Moderate Buy

Company Overview

OptimizeRx Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
25th Percentile Overall Score

OPRX MarketRank™: 

OptimizeRx scored higher than 25% of companies evaluated by MarketBeat, and ranked 566th out of 665 stocks in the computer and technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    OptimizeRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    OptimizeRx has only been the subject of 3 research reports in the past 90 days.

  • Read more about OptimizeRx's stock forecast and price target.
  • Earnings Growth

    Earnings for OptimizeRx are expected to grow in the coming year, from ($0.33) to ($0.29) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of OptimizeRx is -31.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of OptimizeRx is -31.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Growth Ratio

    OptimizeRx has a PEG Ratio of 2.40. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    OptimizeRx has a P/B Ratio of 2.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    6.81% of the float of OptimizeRx has been sold short.
  • Short Interest Ratio / Days to Cover

    OptimizeRx has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in OptimizeRx has recently decreased by 0.87%, indicating that investor sentiment is improving.
  • Dividend Yield

    OptimizeRx does not currently pay a dividend.

  • Dividend Growth

    OptimizeRx does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.81% of the float of OptimizeRx has been sold short.
  • Short Interest Ratio / Days to Cover

    OptimizeRx has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in OptimizeRx has recently decreased by 0.87%, indicating that investor sentiment is improving.
  • News Sentiment

    OptimizeRx has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Computer and Technology companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for OptimizeRx this week, compared to 3 articles on an average week.
  • Search Interest

    14 people have searched for OPRX on MarketBeat in the last 30 days. This is an increase of 56% compared to the previous 30 days.
  • MarketBeat Follows

    13 people have added OptimizeRx to their MarketBeat watchlist in the last 30 days. This is an increase of 1,200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, OptimizeRx insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.60% of the stock of OptimizeRx is held by insiders.

  • Percentage Held by Institutions

    76.47% of the stock of OptimizeRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about OptimizeRx's insider trading history.
Receive OPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OptimizeRx and its competitors with MarketBeat's FREE daily newsletter.

OPRX Stock News Headlines

OptimizeRx announces leadership team advancements
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.tc pixel
Brokerages Set OptimizeRx Corp. (NASDAQ:OPRX) Target Price at $11.81
OptimizeRx (NASDAQ:OPRX) Price Target Raised to $20.00
See More Headlines

OPRX Stock Analysis - Frequently Asked Questions

OptimizeRx's stock was trading at $4.86 at the beginning of the year. Since then, OPRX stock has increased by 250.4% and is now trading at $17.03.

OptimizeRx Corp. (NASDAQ:OPRX) announced its quarterly earnings data on Monday, May, 12th. The company reported $0.08 earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.19. The company had revenue of $21.93 million for the quarter, compared to the consensus estimate of $18.69 million. OptimizeRx had a positive trailing twelve-month return on equity of 4.50% and a negative net margin of 9.42%.
Read the conference call transcript
.

OptimizeRx's top institutional shareholders include Blair William & Co. IL (3.40%), Kennedy Capital Management LLC (2.54%), Manatuck Hill Partners LLC (2.45%) and Geode Capital Management LLC (2.16%). Insiders that own company stock include William J Febbo, James Paul Lang and Marion Odence-Ford.
View institutional ownership trends
.

Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that OptimizeRx investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC).

Company Calendar

Last Earnings
5/12/2025
Today
8/22/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
COMP - SOFTWARE
Sub-Industry
Business Services
Current Symbol
NASDAQ:OPRX
CIK
1448431
Employees
100
Year Founded
N/A

Price Target and Rating

High Price Target
$20.00
Low Price Target
$5.00
Potential Upside/Downside
-30.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
11 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.54)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
2.4
Net Income
-$18.66 million
Net Margins
-9.42%
Pretax Margin
-8.88%
Return on Equity
4.50%
Return on Assets
3.12%

Debt

Debt-to-Equity Ratio
0.21
Current Ratio
2.57
Quick Ratio
2.57

Sales & Book Value

Annual Sales
$104.75 million
Price / Sales
3.02
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.43 per share
Price / Book
2.65

Miscellaneous

Outstanding Shares
18,565,000
Free Float
17,525,000
Market Cap
$316.16 million
Optionable
Optionable
Beta
1.33

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:OPRX) was last updated on 8/22/2025 by MarketBeat.com Staff
From Our Partners